[go: up one dir, main page]

LT3630772T - Pde9 inhibitorių gamybos ir naudojimo būdai - Google Patents

Pde9 inhibitorių gamybos ir naudojimo būdai

Info

Publication number
LT3630772T
LT3630772T LTEPPCT/US2018/034566T LTUS2018034566T LT3630772T LT 3630772 T LT3630772 T LT 3630772T LT US2018034566 T LTUS2018034566 T LT US2018034566T LT 3630772 T LT3630772 T LT 3630772T
Authority
LT
Lithuania
Prior art keywords
manufacturing
methods
pde9 inhibitors
pde9
inhibitors
Prior art date
Application number
LTEPPCT/US2018/034566T
Other languages
English (en)
Inventor
Niels Svenstrup
Jun Zhang
Jikui SUN
Yuyin Chen
Jianshe Kong
Rujian Ma
Junhua Zhang
Liang Qin
Huanming XIAO
Jinxu SUN
Xiao MENG
Fenglai SUN
Jingyang Zhu
Original Assignee
Cardurion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals, Inc. filed Critical Cardurion Pharmaceuticals, Inc.
Publication of LT3630772T publication Critical patent/LT3630772T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2018/034566T 2017-05-26 2018-05-25 Pde9 inhibitorių gamybos ir naudojimo būdai LT3630772T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511367P 2017-05-26 2017-05-26
PCT/US2018/034566 WO2018218104A1 (en) 2017-05-26 2018-05-25 Methods of making and using pde9 inhibitors

Publications (1)

Publication Number Publication Date
LT3630772T true LT3630772T (lt) 2024-02-26

Family

ID=64396048

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/034566T LT3630772T (lt) 2017-05-26 2018-05-25 Pde9 inhibitorių gamybos ir naudojimo būdai

Country Status (23)

Country Link
US (3) US11370795B2 (lt)
EP (1) EP3630772B1 (lt)
JP (1) JP7609518B2 (lt)
KR (1) KR102627975B1 (lt)
CN (2) CN115746003B (lt)
BR (1) BR112019024877A2 (lt)
CA (1) CA3064004A1 (lt)
DK (1) DK3630772T3 (lt)
EA (1) EA201992721A1 (lt)
ES (1) ES2969895T3 (lt)
FI (1) FI3630772T3 (lt)
HR (1) HRP20240146T1 (lt)
HU (1) HUE065158T2 (lt)
IL (1) IL270792B2 (lt)
LT (1) LT3630772T (lt)
MA (1) MA48793A (lt)
MX (2) MX2019014049A (lt)
PL (1) PL3630772T3 (lt)
PT (1) PT3630772T (lt)
RS (1) RS65143B1 (lt)
SI (1) SI3630772T1 (lt)
TW (2) TWI843393B (lt)
WO (1) WO2018218104A1 (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
PL3630772T3 (pl) 2017-05-26 2024-08-05 Cardurion Pharmaceuticals, Inc. Sposoby wytwarzania inhibitora pde9
AU2019275075B2 (en) 2018-05-25 2024-11-28 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7H-imid azo [1,5- a] pyrazin-8-one
CN119679736A (zh) 2018-08-31 2025-03-25 卡都瑞恩医药公司 用于治疗镰状细胞病的pde9抑制剂
CN109734653B (zh) * 2019-02-21 2020-07-14 北京悦康科创医药科技股份有限公司 一种阿加曲班起始原料异构体杂质的拆分方法
WO2020202183A1 (en) * 2019-03-29 2020-10-08 Mylan Laboratories Limited The process for the preparation of upadacitinib and its intermediates
JP2022527630A (ja) * 2019-04-05 2022-06-02 イマラ インク. 鎌状赤血球症を治療するためのpde9阻害剤
WO2022036111A1 (en) * 2020-08-13 2022-02-17 Imara Inc. Methods and compositions for treating sickle cell disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2152412T3 (es) 1994-08-08 2001-02-01 Debiopharm Sa Preparacion farmaceuticamente estable de oxaliplatino.
ES2287238T3 (es) 2001-03-02 2007-12-16 Debiopharm S.A. Utilizacion de un vial que contiene una solucion de oxaliplatino.
PL370599A1 (en) * 2001-11-02 2005-05-30 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
WO2004037311A2 (en) 2002-10-21 2004-05-06 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
AP2524A (en) 2007-05-11 2012-12-04 Pfizer Amino-heterocyclic compounds
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
US20120157458A1 (en) * 2010-09-20 2012-06-21 Amy Ripka Imidazotriazinone compounds
HK1211023A1 (zh) * 2011-10-10 2016-05-13 H. Lundbeck A/S 具有咪唑并吡嗪骨架pde9i
CN107082783B (zh) 2012-01-26 2019-03-22 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
MX365688B (es) 2012-08-31 2019-06-11 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
CA2944480C (en) 2013-04-10 2021-05-18 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
WO2015023557A1 (en) 2013-08-12 2015-02-19 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
PL3630772T3 (pl) * 2017-05-26 2024-08-05 Cardurion Pharmaceuticals, Inc. Sposoby wytwarzania inhibitora pde9

Also Published As

Publication number Publication date
IL270792B2 (en) 2024-01-01
TWI791021B (zh) 2023-02-01
TWI843393B (zh) 2024-05-21
IL270792B1 (en) 2023-09-01
RS65143B1 (sr) 2024-02-29
JP7609518B2 (ja) 2025-01-07
CN111183140A (zh) 2020-05-19
ES2969895T3 (es) 2024-05-23
US11999741B2 (en) 2024-06-04
EP3630772B1 (en) 2023-11-01
DK3630772T3 (da) 2024-02-05
MA48793A (fr) 2020-04-08
PL3630772T3 (pl) 2024-08-05
KR102627975B1 (ko) 2024-01-19
WO2018218104A1 (en) 2018-11-29
BR112019024877A2 (pt) 2020-06-09
CN115746003A (zh) 2023-03-07
TW201908319A (zh) 2019-03-01
CN115746003B (zh) 2024-08-09
HRP20240146T1 (hr) 2024-04-12
EP3630772A4 (en) 2021-01-13
HUE065158T2 (hu) 2024-05-28
CA3064004A1 (en) 2018-11-29
IL270792A (en) 2020-01-30
US20230183244A1 (en) 2023-06-15
EA201992721A1 (ru) 2020-09-10
JP2020527535A (ja) 2020-09-10
US11370795B2 (en) 2022-06-28
MX2019014049A (es) 2020-07-28
MX2023000191A (es) 2023-02-09
TW202334156A (zh) 2023-09-01
PT3630772T (pt) 2024-02-05
EP3630772A1 (en) 2020-04-08
SI3630772T1 (sl) 2024-05-31
CN111183140B (zh) 2022-12-02
US20200157108A1 (en) 2020-05-21
KR20200016891A (ko) 2020-02-17
FI3630772T3 (fi) 2024-01-31
US20250019381A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
IL271025A (en) Multibiotic agents and methods of using the same
LT3618863T (lt) Anti-tigit antikūnai ir jų panaudojimo būdai
LT3601358T (lt) Anti-trem2 antikūnai ir jų naudojimo metodai
LT3630761T (lt) Kras g12c inhibitoriai ir jų naudojimo būdai
IL261625B (en) Inhibitors of menin-mll in bridged cycles and methods of use
LT3653221T (lt) Anti-pvrig antikūnai ir naudojimo būdai
LT3630772T (lt) Pde9 inhibitorių gamybos ir naudojimo būdai
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
PL3215532T3 (pl) Przeciwciała anty-TIM3 i sposoby ich zastosowania
DK3205650T3 (da) Egfr-hæmmer og fremstilling og anvendelse deraf
PT3548033T (pt) Compostos e respectivos métodos de utilização
LT3514151T (lt) Proteinkinazės c inhibitoriai ir jų naudojimo būdai
PL3828194T3 (pl) Oksysterole i sposoby ich stosowania
LT3525583T (lt) Anti-c1s antikūnai ir jų naudojimo būdai
LT3436022T (lt) Oksisteroliai ir jų panaudojimo būdai
LT3452485T (lt) Arginazės inhibitoriai ir jų terapinis taikymas
PL3371206T3 (pl) Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka
IL283782A (en) Anellosomes and methods of use
PL3812392T3 (pl) Oksysterole i sposoby ich stosowania
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
IL272851A (en) Methods of using dipivefrin
LT3490988T (lt) Naujas junginys ir gavimo būdas
LT3562790T (lt) Pagrindų ir susijusių pagrindų atskyrimo būdas
LT3606929T (lt) Beta-nikotinatinato esterio nukleotidai ir jų gamybos būdai
LT3532059T (lt) Bromodomeno ir papildomo galinio baltymo inhibitorių derinio terapija